Prevention of Post-Transfusion Hepatitis by Screening of Antibody to Hepatitis B Core Antigen in Healthy Blood Donors by Shastry, S. & Bhat, S.S.
Mediterr J Hematol Infect Dis 2011; 3; Open Journal Syst
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES
Original Articles
Prevention of Post-Transfusion Hepatitis 
Core Antigen in Healthy Blood Donors
S. Shastry and S.S. Bhat. 
Department  of  Immunohematology  and  Blood  Transfusion
Karnataka, India.
Correspondence  to:  Dr  Shamee  Shastry
Transfusion,  Kasturba  Medical  College, 
2922448. E-mail: shameegirish@gmail.co
Competing interests: The authors have d
Published: December 18, 2011
Received: July 15, 2011
Accepted: November 9, 2011
Mediterr J Hematol Infect Dis 2011, 3(1): e2011062, DOI 10.4084/MJHID.2011.062
This article is available from: http://www.mjhid.org/article/view/8841
This  is  an  Open  Access  article  distributed  under  the  terms  of  the  Creative  Commons  Attribution  License 
(http://creativecommons.org/licenses/by/2.0
provided the original work is properly cited.
Abstract. Background: Transfusion
problem in India even after adoption of mandatory screening for HBsAg by ELISA method. The 
high incidence of TAHBV is reported in patients receiving multiple transfusions.
Objective: To study the seroprevalence of hepatitis B core antibody among healthy voluntary blood 
donors
Subjects and Methods: The study was conducted in the department of Transfusion Medicine of a 
tertiary  care referral  hospital.  A total  of  12,232  volunteers  after
criteria were selected for blood donation. Donor samples were tested for all mandatory transfusion 
transmissible infections and anti HBc IgM (Monolisa HBc IgM PLUS:BIO
results  were  confirmed  by  repeat  t
software  and  Chi-square  test  was  used  to  calculate  the  significance  of  difference  between  the 
groups.
Results:A total of 12,232 healthy voluntary blood donors were recruited. Majority (93.4%) were 
males. Median age of donor population was 26 years (range: 18
positive for HBsAg, which comes under “low prevalence (<2%) zone” as per WHO. On screening 
for HBcAg Ig M, 15 (0.1%) were found to be positive and none were HBsA
significance of difference in the mean age between reactive and non
Conclusion:Evaluating the usefulness of anti
may be included in routine screening of donors a
period. The cost and the unnecessary wastage of the blood units when they are positive for anti 
HBsAg along with the core antibody need to be studied.
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Transfusion-associated hepatitis B viral infection continues to be a major 
problem in India even after adoption of mandatory screening for HBsAg by ELISA method. The 
high incidence of TAHBV is reported in patients receiving multiple transfusions.
To study the seroprevalence of hepatitis B core antibody among healthy voluntary blood 
The study was conducted in the department of Transfusion Medicine of a 
tertiary  care referral  hospital.  A total  of  12,232  volunteers  after passing  through  the  stringent 
criteria were selected for blood donation. Donor samples were tested for all mandatory transfusion 
transmissible infections and anti HBc IgM (Monolisa HBc IgM PLUS:BIO-
results  were  confirmed  by  repeat  testing  in  duplicate.  Donor  data  was  analyzed  using  SPSS 
square  test  was  used  to  calculate  the  significance  of  difference  between  the 
A total of 12,232 healthy voluntary blood donors were recruited. Majority (93.4%) were 
ales. Median age of donor population was 26 years (range: 18-60 years). Eighty six (0.7%) were 
positive for HBsAg, which comes under “low prevalence (<2%) zone” as per WHO. On screening 
for HBcAg Ig M, 15 (0.1%) were found to be positive and none were HBsAg reactive. There was no 
significance of difference in the mean age between reactive and non-reactive donors. 
Evaluating the usefulness of anti-HBc screening is critical. Anti HBcAg IgM screening 
may be included in routine screening of donors as it is an indicator of occult HBV during window 
period. The cost and the unnecessary wastage of the blood units when they are positive for anti 
HBsAg along with the core antibody need to be studied.
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Introduction. The  risk  reduction  strategies  for 
transfusion  transmissible  infections  are  adopted  at 
various  stages  in  transfusion  centers.  It  includes  the 
detailed donor interview, review of the donor history,  
careful  medical  selection  of  the  blood  donors, 
maintenance of donor deferral register, elimination of 
cash  payment  to  donors,  and  using  of  sensitive 
serological  tests  in  the  laboratory.  Transfusion-
associated  hepatitis  B  viral  infection  (TAHBV) 
continues  to  be  a  major  problem  in  developing 
countries,  even  after  the  adoption  of  mandatory 
screening  for  HBsAg  by  ELISA  method.    The  high 
incidence of transfusion associated hepatitis B virus  is 
reported in patients receiving multiple transfusion like 
thalassemia  and  hemato-oncology  patients.  This  is 
mainly  because  of  the  blood  from  the  donors  with 
‘occult’ HBV  infection  (OBI).  This  condition  is 
defined  as  viral  DNA  without  detectable  HBsAg 
observed  after  the  initial period  of  primary  infection 
and most of the time accompanied by the presence of 
anti-HBc.  Thus the absence of HBsAg in the blood of 
apparently healthy individuals may not be sufficient to 
ensure  the  lack  of  circulating  HBV.  and  blood 
containing  anti-hepatitis  B  core  antibody  (anti-HBc) 
without  detectable  presence  of  HBsAg  might  be 
infectious.  However  implimentation of  nucleic  acid 
testing (NAT) reduces the risk of residual infection it 
may not be economically feasible at every blood bank 
in  our  country.  In  this  context  we  studied  the 
seroprevalence  of  hepatitis  B  core  antibody  (Ig  M) 
among  blood  donors  at  our  center.  We  have  also 
studied the effect of core antibody testing on discard 
rate of blood. This is the first study of seroprevalence 
of  hepatitis  B  core  antibody  in  South  Indian  blood 
donors. 
Subjects and Methods. The study was conducted in 
the department of Transfusion Medicine of a tertiary 
care  referral  hospital  situated  at  the  costal  part  of 
Karnataka  State  (Udupi district,  India).    A  total  of 
12,232 volunteers were selected after passing through 
the stringent criteria for blood donation.
1 The family 
members,  friends  or  relatives  of  the  patients  were 
categorized as replacement donors.  People who donate 
blood  without  expecting  any  favor  in  return  were 
classified  as  voluntary  blood  donors.  Donors  with 
history  of  jaundice,  hepatitis  and  high  risk  behavior 
were  deferred.  All  the  donors  were  counseled  and 
informed about the tests carried out on the collected 
blood  units.  The  blood  samples  were  tested  for  all 
mandatory  transfusion  transmissible  infections  like 
HIV(Genscreen  ULTRA,  HIV  Ag-Ab.  BIO-RAD, 
France),  HCV(SP  NANBASE  General  Biologicals 
Corp.  Taiwan),  HBV(MonalisaTM  HBsAg  ULTRA, 
BIO-RAD, France), Syphilis (RPR, BIO-RAD, France)  
&  Malaria  (Qualisa  Malaria,  Qualpro  Diagnostics, 
Tulip  Group.  Goa,  India)  by  ELISA,  Rapid  Plasma 
Reagin  testing  and  thick  smear  examinations 
respectively.  In addition to these tests, ELISA for anti 
HBc  IgM  (Monolisa  HBc  IgM  PLUS:BIO-RAD, 
France) was done. The sensitivity anti HBc IgM assay 
is  98.5%  with  analytical  sensitivity  of  50U/ml  and 
specificity is 99.9% as mentioned in the product insert 
provided in the kit. ELISA for all the 4 markers (HIV, 
HCV,  HBsAg,  anti  HBc  IGM)  were  done 
simultaneously  using  a  4  plate  automated  ELISA 
equipment  (EVOLIS  by  Bio  RAD).  Reactive  results 
were confirmed by repeating the test in duplicate. On 
confirming  the  results,  as  per  our  departmental 
standard  operating  protocol  we  inform  the  donor 
confidentially. Donor demographic data was obtained 
and  compared  between  reactive  and  non-reactive 
groups. Data was analyzed using SPSS software and 
Chi-square test was used to calculate the significance 
of difference between the groups.
Results. A total of 12232 healthy blood donors who 
have passed the stringent donor selection criteria were 
recruited for this study over a period of one year (2009-
2010).  Among  them  8865  (72.47%)  were  voluntary 
blood  donors  and  3367  (27.52%)  were  replacement 
blood  donors.    A  majority  (11403,  93.2%)  of  them 
were males.  Median age of donor population was 26 
years  (range:18-60  years).    Eighty  six  blood  donors 
(0.7%)  were  positive  for  HBsAg.  On  screening  for 
anti-HBc  (IgM),  15  (0.12%)  samples  gave  reactive 
results and all of them were negative for HBsAg.  Anti-
HBc  (IgM)  reactivity  was  0.03%  among  voluntary 
blood donors and, 0.35% in replacement donors (Table 
1) and seroprevalence was significantly higher among 
replacement donors than the voluntary ones. Among 15 
core antibody reactive donors only one was a female 
donor. Seroprevalence among male donors was 0.12% 
(14/11403)  and  among  female  donors  was    0.11% 
(1/892),  there  was  no  significant  difference  between 
the  two  groups.  On  analyzing  the  occupation  of  the 
blood donors who were reactive for core antibody, 33% 
were  students,  26%  were  businessmen  and  40%    as 
servicemen (2), electricians (2), driver (1) and barber 
(1). A decreasing trend of core antibody reactivity was 
observed  with  the  increasing  age  of  the  donors.  
Seroprevalence  of  core  IgM  antibody  was  high  in 
young donors with the age of <20 years and  it is the 
lowest in donors between 31 to 40 yrs of age (Figure 
1).  
Sample to cut-off ratio of OD values ranged from 
1.00 to 8.69 (<1.5: in 8 cases, 1.5 – 2.5: In 3 cases, > 
2.5: In 3 cases). Cost analysis showed an addition of 
Rs.100/- per test when core antibody testing was done 
in addition to the other mandatory infection screening Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
Table 1. Hepatitis B Core antibody reactivity among different types 
of blood donors.
Blood donors
Anti HBc (IgM)
p-value Reactive Nonreactive
Voluntary 3 8862
0.000 Replacement 12 3355
Male 14 11389
0.730 Female 1 828
tests.  Discard rate of blood was 0.88% per year due to 
HBV  infection  (HBsAg);  with  the  addition  of  core 
antibody testing (IgM) discarding rate of increased to 
0.97% per year.
Discussion. Post transfusion hepatitis is common even 
after  practicing  the  stringent  donor  selection  criteria 
and screening the blood for HBsAg. This is because a 
considerable number of HBV infected donors remained 
undiagnosed, if only HBsAg is used for screening. We 
have  studied  the  seroprevalence  of  hepatitis  B  core 
antibody  among  the  donor  population  of  costal 
Karnataka,  southern  part  of  India.  Knowing  the 
seroprevalence rate of the core antibody will provide 
an idea about the usefulness of the implementation of 
routine core antibody testing for blood donor screening 
purpose.  In the  present  study  we  have  used  the  kits 
detecting only Ig M type of antibody. The prevalence 
rate  of  core  antibody  is  found  to  be  0.12%  in  the 
present study. 
HBV DNA was detected in 3.3% to 30% of  the 
blood  donors those  who are  negative for  hepatitis B 
surface  antigen  (HbsAg)  and  hepatitis  B  surface 
antibody  (HBsAb) but  positive  for  anti-HBc  .
2,3 As 
shown in various studies the prevalence of anti HBc 
antibody  among  blood  donors  varies  from  0.12%  to 
19% (Table 2). The seroprevalence rate of anti HBc 
IgM in the south Indian population is not available and 
the present study shows a low prevalence rate in this 
part  of  country.  Most  of  the  studies  from  India  and 
other  countries  showing  high  seroprevalence  of  core 
antibody have used kits with total anti HBc. A donor 
with  a  positive  anti  HBc-IgG  indicates  either  a  past 
infection or a carrier state. Anti-HBc IgG may remain 
positive for life in an affected individual although the 
individual  has  protective  levels  of  anti-HBs  and 
therefore, this does not necessarily mean that blood of 
such  a  donor  is  infectious.  However  unless  we  do
sensitive  NAT  we  can’t  confirm  the  presence  or 
absence of the virus in such donor. Unlike IgG subtype 
anti-HBc  IgM  is  a  marker  of  recent  hepatitis  B 
infection.
Our finding of significantly higher seroprevalence 
of core antibody among replacement donors supported 
the national policies aiming towards 100% voluntary 
blood donation.  Study done by Asim et al showed a 
difference  in  the  seroprevalence  of  core  antibody 
between male and female donors (19.3% Vs 18%) but 
as  in  our  study the  difference  was  statistically  not 
significant.
5 We have observed an alarmingly high rate 
of core antibody positivity among younger population 
(with age <20 years) in contrary to the study done by
Seo et al, which showed increasing prevalence of core 
antibody  with  the  increasing  age  of  the  donor
population.
7 Thirty three percent of reactive donors in 
our study were students. Higher rate prevalence among 
younger  population  shows  the  need  for effective 
implementation  of  preventive  measures,  such as 
Figure 1. Seroprevalence of Hepatitis B Core antibody and HBsAg in different age groups of blood donors.
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Table 2. Comparison of Seroprevalence of Anti HBc from various 
studies.
Place Seroprevalence 
of Anti HBc  Year [Reference]
Costal Karnataka (India) 0.12% 2010 [present 
study]
Chandigarh (India) 8.4% 2006 [4]
New Delhi (India) 18.9% 2006 [5]
New Delhi (India)
0.43% (IgM)
2007[6]
15.9% (total)
Korea 13.5% 2008[7]
Pakistan 19.15% 2005 [8]
Iran 6.55% 2002 [9]
Italy 4.85% 2005 [10]
Turkey 15% 2006 [11]
Germany  1.52% 2002 [12]
Egypt 7.8% 2010 [13]
prenatal  testing  of  HBsAg  in  pregnant  women  and 
vaccination  program.  As  per  Indian  Academy  of
Pediatrics, current immunization schedule for hepatitis 
B vaccination is, first dose at birth, second dose at 6 
weeks and third dose at 6 months of age. The Hepatitis 
B Project was initiated in India in the year 2002 with 
support  of  Global  Fund  for  vaccines  and 
immunization.
14 In  addition  to  these  measures, 
inclusion of educative sessions on health and hygiene 
may be helpful in creating awareness among younger 
population. 
Screening of blood units for core antibody adds to 
the cost, but definitely useful in reducing the residual 
risk  of  post  transfusion  hepatitis.  The  false  reactive 
results  is  another  disadvantage  of  highly  sensitive 
assays and in the present study we could not do the 
complete HBV panel. That is a limitation of our 
study. A study done in North India using IgM alone 
showed a little higher seroprevalence of 0.43% than the 
present  study.
6 However  the  core  antibody  reactivity 
rate  was  too  high  (15.9%)  when  they  used  kits 
containing both IgG and IgM. It may not be practical 
for any blood bank to discard such a huge amount of 
blood  units.  And  in  majority  of  blood  banks  in 
developing  countries    NAT  may  not  be  feasible.  As 
mentioned by Allain et al HBV NAT is a multi-step 
process  and  each  of  the  steps  is  necessary  and 
complementary  of  the  preceding  one.  Information 
provided  by  the  serological  markers  is  important  to 
determine whether the donor is truly infected or not. 
The key marker at this step is anti-HBc. In an area with 
low HBV infection prevalence, the association of anti 
HBc  with  HBV  DNA  is  strongly  suggestive  of  an 
established infection. Whereas in high endemic areas, 
the value of the information is limited since a majority 
of  the  population  of  blood  donation  age  carries  anti 
HBc.
15 Therefore,  the  role  of  anti-HBc  in  detecting 
blood donors with occult hepatitis B infection need to 
be considered separately in various countries.
16 Occult 
hepatitis B infection has a major impact on transfusion 
safety.  The  standard  test  for  detection  of  occult 
infection is the amplification of HBV DNA. However, 
the  serological  assay  for  the  long  lasting  antibody 
response to the highly immunogenic HBV core antigen 
represents a qualified candidate as a surrogate for DNA 
amplification.
16 Although HBs Ag seroprevalence rate 
in  our  study  is  <2%  ,  which  comes  under  the  low 
prevalence  area  as  per  WHO  guidelines,  the 
implementation  of  core  antibody  testing  becomes 
important step towards continual improvement in blood 
safety.
Conclusion.  Evaluating  the  usefulness  of  anti-HBc 
screening is critical. Anti HBcAg IgM screening may 
be included in routine screening of donors as it is an 
indicator of  recent HBV infection and is the marker 
which  is  helpful  in  detection  of  HBV  infection  in 
HBsAg    window  period.  Costal  Karnataka  is  a  low 
prevalence area (<2%) for hepatitis B infection. In such 
areas the blood discarding rate due to core antibody is 
not  high  when  the  kits  with  Ig  M  antibody  alone  is 
used.  The  cost  and  the  unnecessary  wastage  of  the 
blood  units  when  they  are  positive  for  anti  HBsAg 
along  with  the  core  antibody  need  to  be  studied.  
Analysis  of  cost-effectiveness will  be  helpful  in 
making  a  policy  decision  for  the  implementation  of 
routine screening for hepatitis B core antibody.
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